Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
3 minute read

Lifeist Reports Highest Quarterly Gross Profit In History, Continues To Diversify Its Wellness Business

By Jelena Martinovic
April 2, 10:13 AM
Lifeist Wellness Inc. reported on Monday its financial results for the three and 12 months ended Nov. 30, 2023. The Toronto-based company said it achieved the highest quarterly gross profit in the company's history in the fourth quarter totaling CA$2 million ($1.5 million), representing a gross margin of 42%, compared to CA$1.9 million, or 31% gross margin, in the corresponding quarter of 2022."Our performance in the fourth quarter of 2023 reflects our strategic focus on high-margin activities and operational efficiency, resulting in the highest quarterly gross profit in our company's history," Meni Morim, CEO of Lifeist, said. "Though accompanied by unique hurdles, our focus towards enhancing gross profit has produced promising results." The company recently announced that it has entered into a definitive share purchase agreement with 1463663 B.C. Ltd., a newly incorporated affiliate of Tierra Corp., and the company's Canadian cannabis subsidiaries, collectively referred to as the CannMart Group, to divest and sell all of the shares of the CannMart Group to the buyer for CA$5 million.

LFST

Read More
2 minute read

Cannabinoid-Based Products Maker Sees Triple-Digit Growth In 2023 Gross Profit, Revenue Surges 314% YoY

By Jelena Martinovic
April 2, 9:18 AM
Cannabinoids-focused biopharmaceutical company Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) reported on Tuesday year-end 2023 results and audited financial statements. The Canadian company reported CA$16.8 million ($12.3 million) in total revenue, up by 314% year-over-year. Avicanna mostly attributed a surge in revenue to the acquisition of Medical Cannabis by Shoppers from Shoppers Drug Mart and the launch of MyMedi.ca. "2023 was a tremendous year for Avicanna where we solidified our leadership position in the Canadian medical cannabis sector through our proprietary products and the launch of MyMedi.ca," he said. "We have successfully demonstrated the scalability of our revenues and made significant improvements in our fundamentals while advancing all our business pillars."

AVCNF

Read More
2 minute read

Hydroponics Giant Announces $6M Share Repurchase Program, CEO Says Understanding ‘Where Every Nickel Goes’ Is Vital For Business Growth

By Jelena Martinovic
March 28, 12:20 PM
Beginning on April 1, the share repurchase program, will continue for up to one year, allowing for repurchases to be made in the open market. Darren Lampert, the company's co-founder and CEO, explained what the move means for GrowGen. "Today's announcement of our share repurchase program further underscores our conviction in the strength of our underlying business and our view that GrowGen shares remain undervalued," Lampert said. "This program acts as one pillar of our shareholder value creation strategy as we continue to evaluate all potential uses for our strong balance sheet, including reinvesting in our brands, strategic acquisitions, and stock repurchases to enhance long-term shareholder value."

GRWG

Read More
2 minute read

Hemp-Focused Wellness Co. Moves Closer To Profitability, Reports Flat 2023 Revenue, Increase In Gross Profit

By Jelena Martinovic
March 28, 12:04 PM
Hemp-focused consumer wellness company CV Sciences, Inc. (OTCQB: CVSI) announced on Thursday its financial results for the year ended Dec. 31, 2023. The San Diego-based company reported a gross margin of 44.3% for fiscal year 2023, representing an improvement from 34.2% for 2022. For the fourth quarter gross margin was 45.8%, representing a sequential improvement from 45.1% in the third quarter. "Our 2023 progress demonstrates our continuous commitment to innovation and cost-efficient execution as we move closer to profitability and positive cash flow," Joseph Dowling, CEO of CV Sciences, said. "As the CBD category consolidates, we have increased our market share in key sales channels, including the natural product retail channel. We will continue to focus our resources on new product development, as evidenced by our pet line expansion with our recent launch of pet chews for hip and joint health and calming care."

CVSI

Read More
3 minute read

IM Cannabis’ Q4 Revenue: Gross Profit Drops Due To Negative Impact Of Israel-Hamas War, Sees Germany As Growth Opportunity

By Jelena Martinovic
March 28, 11:19 AM
IM Cannabis Corp. (NASDAQ: IMCC) (CSE: IMCC) announced on Thursday its financial and operational results for the year ended Dec. 2023. The Toronto-headquartered medical cannabis company with a focus on Israel and Germany reported a 10% year-over-year decrease in revenue to CA$48.8 million ($36 million) in 2023. IM Cannabis attributed it to "negative currency fluctuations and the impact of the Israel-Hamas war on the company's operations." Fourth quarter revenue dropped 26% year-over-year to CA$10.7 million. "As previously warned and as expected, unfortunately, the Israel-Hamas war had a negative impact on our fourth quarter 2023 results, which weighed on our full-year results.," Uri Birenberg, chief financial officer of IMC, said. "Coupled with our fourth quarter of 2023 inventory reduction, the war caused our fourth quarter gross profit to decrease by 68% as compared to the fourth quarter of 2022."

CSE:IMCC

Read More
2 minute read

This Cannabinoids-Focused Pharma Co. Sees 50% YoY Surge In Revenue In 2023, Trims Losses

By Jelena Martinovic
March 27, 6:32 PM
Cannabinoids-focused pharmaceutical company MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) announced on Wednesday its financial results for the full year and three months ended Dec. 31, 2023. Net revenue grew to CA$33 million ($24.3 million), from CA$22.1 million in 2022, representing roughly a 50% year-over-year increase. "Over the years we have invested in our infrastructure as a high quality and high-capacity pharmaceutical grade manufacturer, allowing us to grow sales with new opportunities and markets, without additional investment into capital or resources," David Pidduck said. "We are proud of the work completed in 2023 and excited about the future of MediPharm Labs."

MEDIF

Read More
2 minute read

Body and Mind’s Q2 Revenue Flat YoY, Narrows Loss By 94%

By Jelena Martinovic
March 26, 2:16 PM
Body and Mind announced on Tuesday its financial results for the second quarter of fiscal year 2024 ended Jan. 31, 2024, revealing a 94% year-over-year drop in net loss. The company said that during the quarter it has entered into a definitive agreement to divest its Nevada cultivation and production operations for a total consideration of $2 million to fund its projects in Illinois and New Jersey. According to CEO Michael Mills these two markets "continue to be underserved and offer significant opportunities for revenue growth as we expand our brand and bring our skilled teams to these new markets." "The most recent quarter reflects our work to improve financial performance, improve margins and streamline our operations to support building our operations in Illinois and New Jersey," Mills said. "Nevada's wholesale pricing challenges and wholesale tax structure made it difficult to see the Company's Nevada operations generating sufficient profits over the long term when compared with the opportunity presented by taking the proceeds from Nevada's sale and continuing to build on our Illinois and New Jersey opportunities."

BMMJ

Read More
2 minute read

Morningstar Trims Tilray’s Price Target, Here’s What’s Behind It

By Jelena Martinovic
February 20, 2:33 PM
Morningstar reduced its price target for Tilray Brands, Inc. (NASDAQ: TLRY) from $3.30 to $3.10, on Wednesday, Feb 14, all while keeping its four-star rating intact. According to Kristoffer Inton, the analyst, three reasons contributed to the price decline, including reduced revenue in the short term driven by ongoing market fragmentation, pricing compression, and still present illicit market in Canada."We forecast CAGR for net revenue from cannabis to be roughly 8% through fiscal 2033," the analyst said. "Our forecast is based on moderate price increases of roughly 3% per year, with weaker price growth in the Canadian recreational market due to Canadian consumers' preference for value over premium."

CSE:MMEN

Read More
3 minute read

Top Cannabis Appointments You Should Know About: Aurora’s New CFO And Other Changes

By Jelena Martinovic
February 20, 10:11 AM
Cannabis multi-state operator Cresco Labs kicked off February by announcing the promotion of Greg Butler to the position of president. Tom Shuman, a CPG sales and marketing veteran, agreed to serve as The Hempshire Group's new CEO. Los Angeles-based STIIIZY INC. named Isaac Kim its new CFO earlier this month. Another California-based cannabis operator Lowell Farms appointed Jamie Schniedwind as its new director of finance. The Colorado-based medical cannabis pioneer Charlotte's Web Holdings tapped Matthew E. McCarthy, the former CEO of Ben & Jerry's Homemade, to serve on its board earlier this month. Aurora Cannabis has named Simona King, a former executive of Bristol Myers-Squibb, its new CFO.

ACB